|
Volumn 11, Issue 3, 2002, Pages 323-329
|
Hyperlipidemia in kidney disease: Causes and consequences
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTILIPEMIC AGENT;
APOLIPOPROTEIN E;
ATORVASTATIN;
CERIVASTATIN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
FOSINOPRIL;
HIGH DENSITY LIPOPROTEIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN;
PRAVASTATIN;
SIMVASTATIN;
VERY LOW DENSITY LIPOPROTEIN;
ANIMAL MODEL;
CARDIOVASCULAR DISEASE;
CHRONIC DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DIABETES MELLITUS;
DISEASE COURSE;
DOUBLE BLIND PROCEDURE;
DYSLIPIDEMIA;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPERLIPIDEMIA;
HYPERTRIGLYCERIDEMIA;
KIDNEY DISEASE;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
META ANALYSIS;
MULTICENTER STUDY;
NONHUMAN;
PATHOGENESIS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RAT;
REVIEW;
RHABDOMYOLYSIS;
SYSTEMIC LUPUS ERYTHEMATOSUS;
GRAFT REJECTION;
RENAL REPLACEMENT THERAPY;
CARDIOVASCULAR DISEASES;
CHRONIC DISEASE;
DISEASE PROGRESSION;
GRAFT REJECTION;
HUMANS;
HYPERLIPIDEMIAS;
KIDNEY DISEASES;
KIDNEY TRANSPLANTATION;
RENAL DIALYSIS;
|
EID: 0036257066
PISSN: 10624821
EISSN: None
Source Type: Journal
DOI: 10.1097/00041552-200205000-00009 Document Type: Review |
Times cited : (35)
|
References (53)
|